Literature DB >> 22983443

ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.

Joost H A Martens1, Amit Mandoli, Femke Simmer, Bart-Jan Wierenga, Sadia Saeed, Abhishek A Singh, Lucia Altucci, Edo Vellenga, Hendrik G Stunnenberg.   

Abstract

ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs and identified ERG/FLI1 as proteins that facilitate binding of oncofusion protein complexes. In addition, we demonstrate that ERG and FLI1 bind the RUNX1 promoter and that shRNA-mediated silencing of ERG leads to reduced expression of RUNX1 and AML1-ETO, consistent with a role of ERG in transcriptional activation of these proteins. Finally, we identify H3 acetylation as the epigenetic mark preferentially associated with ETS factor binding. This intimate connection between ERG/FLI1 binding and H3 acetylation implies that one of the molecular strategies of oncofusion proteins, such as AML1-ETO and PML-RAR-α, involves the targeting of histone deacetylase activities to ERG/FLI1 bound hematopoietic regulatory sites. Together, these results highlight the dual importance of ETS factors in t(8;21) leukemogenesis, both as transcriptional regulators of the oncofusion protein itself as well as proteins that facilitate AML1-ETO binding.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22983443      PMCID: PMC3496958          DOI: 10.1182/blood-2012-05-429050

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

Review 1.  The biology of hematopoietic stem cells.

Authors:  S J Morrison; N Uchida; I L Weissman
Journal:  Annu Rev Cell Dev Biol       Date:  1995       Impact factor: 13.827

2.  Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors.

Authors:  T Okuda; Z Cai; S Yang; N Lenny; C J Lyu; J M van Deursen; H Harada; J R Downing
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

3.  Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.

Authors:  D A Yergeau; C J Hetherington; Q Wang; P Zhang; A H Sharpe; M Binder; M Marín-Padilla; D G Tenen; N A Speck; D E Zhang
Journal:  Nat Genet       Date:  1997-03       Impact factor: 38.330

4.  The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus.

Authors:  H de Thé; C Chomienne; M Lanotte; L Degos; A Dejean
Journal:  Nature       Date:  1990-10-11       Impact factor: 49.962

5.  Prognostically useful gene-expression profiles in acute myeloid leukemia.

Authors:  Peter J M Valk; Roel G W Verhaak; M Antoinette Beijen; Claudia A J Erpelinck; Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Judith M Boer; H Berna Beverloo; Michael J Moorhouse; Peter J van der Spek; Bob Löwenberg; Ruud Delwel
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

6.  E protein silencing by the leukemogenic AML1-ETO fusion protein.

Authors:  Jinsong Zhang; Markus Kalkum; Soichiro Yamamura; Brian T Chait; Robert G Roeder
Journal:  Science       Date:  2004-08-27       Impact factor: 47.728

7.  Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML.

Authors:  A Kakizuka; W H Miller; K Umesono; R P Warrell; S R Frankel; V V Murty; E Dmitrovsky; R M Evans
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

8.  Cooperative binding of Ets-1 and core binding factor to DNA.

Authors:  D Wotton; J Ghysdael; S Wang; N A Speck; M J Owen
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

Review 9.  The Runx genes: lineage-specific oncogenes and tumor suppressors.

Authors:  Ewan R Cameron; James C Neil
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

Review 10.  Core-binding factors in hematopoiesis and immune function.

Authors:  Marella F T R de Bruijn; Nancy A Speck
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

View more
  55 in total

1.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

2.  A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.

Authors:  Shan Lin; Anetta Ptasinska; Xiaoting Chen; Mahesh Shrestha; Salam A Assi; Paulynn S Chin; Maria R Imperato; B J Aronow; Jingsong Zhang; Matthew T Weirauch; Constanze Bonifer; James C Mulloy
Journal:  Blood       Date:  2017-07-14       Impact factor: 22.113

Review 3.  The RUNX1-PU.1 axis in the control of hematopoiesis.

Authors:  Maria Rosaria Imperato; Pierre Cauchy; Nadine Obier; Constanze Bonifer
Journal:  Int J Hematol       Date:  2015-03-08       Impact factor: 2.490

4.  E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia.

Authors:  Wen-Chieh Pi; Jun Wang; Miho Shimada; Jia-Wei Lin; Huimin Geng; Yu-Ling Lee; Rui Lu; Dongxu Li; Gang Greg Wang; Robert G Roeder; Wei-Yi Chen
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

5.  GFI1 is required for RUNX1/ETO positive acute myeloid leukemia.

Authors:  Anna E Marneth; Lacramioara Botezatu; Judith M Hönes; Jimmy C L Israël; Judith Schütte; Lothar Vassen; Robert F Lams; Saskia M Bergevoet; Laura Groothuis; Amit Mandoli; Joost H A Martens; Gerwin Huls; Joop H Jansen; Ulrich Dührsen; Tobias Berg; Tarik Möröy; Christian Wichmann; Mia-Chia Lo; Dong-Er Zhang; Bert A van der Reijden; Cyrus Khandanpour
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

6.  Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia.

Authors:  Florentien E M In 't Hout; Mylène Gerritsen; Lars Bullinger; Bert A van der Reijden; Gerwin Huls; Edo Vellenga; Joop H Jansen
Journal:  Haematologica       Date:  2019-12-19       Impact factor: 9.941

7.  Definition of a small core transcriptional circuit regulated by AML1-ETO.

Authors:  Kristy R Stengel; Jacob D Ellis; Clare L Spielman; Monica L Bomber; Scott W Hiebert
Journal:  Mol Cell       Date:  2020-12-30       Impact factor: 17.970

8.  CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.

Authors:  A Mandoli; A A Singh; P W T C Jansen; A T J Wierenga; H Riahi; G Franci; K Prange; S Saeed; E Vellenga; M Vermeulen; H G Stunnenberg; J H A Martens
Journal:  Leukemia       Date:  2013-09-04       Impact factor: 11.528

9.  A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia.

Authors:  Yun Tan; Xiaoling Wang; Huan Song; Yi Zhang; Rongsheng Zhang; Shufen Li; Wen Jin; Saijuan Chen; Hai Fang; Zhu Chen; Kankan Wang
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

10.  Structural and dynamic studies of the transcription factor ERG reveal DNA binding is allosterically autoinhibited.

Authors:  Michael C Regan; Peter S Horanyi; Edward E Pryor; Jessica L Sarver; David S Cafiso; John H Bushweller
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.